Pharming Reports Q4 2025 Earnings with Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Should l Buy PHAR?
Source: seekingalpha
- Earnings Highlights: Pharming's Q4 2025 GAAP EPS stands at $0.01, aligning with expectations, while revenue reaches $106.5 million, reflecting a 14.9% year-over-year growth and exceeding market expectations by $0.6 million, indicating the company's stable performance in the market.
- RUCONEST® Revenue Growth: RUCONEST® generated $86.7 million in revenue, marking a 9% increase compared to Q4 2024, highlighting sustained demand for the product and the company's competitive position in this segment.
- Strong Joenja® Performance: Joenja® saw a remarkable 53% revenue increase to $19.8 million in Q4, showcasing the product's market acceptance and the success of the sales strategy, which is expected to further drive overall company performance.
- Cash Flow and Future Outlook: Operating cash flow amounted to $10.7 million, up from $9.3 million in Q4 2024, while cash and cash equivalents rose from $168.9 million to $181.1 million; the 2026 total revenue guidance of $405 million to $425 million reflects the company's confidence in future growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHAR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHAR
Wall Street analysts forecast PHAR stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 15.880
Low
37.00
Averages
39.50
High
42.00
Current: 15.880
Low
37.00
Averages
39.50
High
42.00
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pharming Reports Q4 2025 Earnings with Revenue Growth
- Earnings Highlights: Pharming's Q4 2025 GAAP EPS stands at $0.01, aligning with expectations, while revenue reaches $106.5 million, reflecting a 14.9% year-over-year growth and exceeding market expectations by $0.6 million, indicating the company's stable performance in the market.
- RUCONEST® Revenue Growth: RUCONEST® generated $86.7 million in revenue, marking a 9% increase compared to Q4 2024, highlighting sustained demand for the product and the company's competitive position in this segment.
- Strong Joenja® Performance: Joenja® saw a remarkable 53% revenue increase to $19.8 million in Q4, showcasing the product's market acceptance and the success of the sales strategy, which is expected to further drive overall company performance.
- Cash Flow and Future Outlook: Operating cash flow amounted to $10.7 million, up from $9.3 million in Q4 2024, while cash and cash equivalents rose from $168.9 million to $181.1 million; the 2026 total revenue guidance of $405 million to $425 million reflects the company's confidence in future growth prospects.
See More
Pharming Group Reports Strong Q4 2025 Earnings Growth
- Significant Revenue Growth: Pharming Group reported total revenues of $106.5 million in Q4 2025, reflecting a 15% year-over-year increase, while full-year revenues grew by 27% to $376.1 million, showcasing the company's strong growth potential in the biotech sector.
- Improved Profitability: The company achieved an operating profit of $26 million in 2025, a substantial turnaround from a loss in 2024, with Q4 operating cash flow reaching $55 million, enhancing financial stability and cash reserves compared to the end of 2024.
- Strong Product Performance: RUCONEST delivered a 26% global revenue growth, while Joenja reached $19.8 million in Q4 2025, marking a 53% increase year-over-year, indicating resilience in market competition and robust product demand.
- Optimistic Outlook: Pharming reaffirmed its 2026 revenue guidance of $405 million to $425 million, expecting continued growth for RUCONEST and Joenja despite new competitive pressures, with management expressing confidence in future market expansion and R&D investments.
See More
Pomerantz LLP Investigates Pharming Group for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Pharming Group N.V. regarding potential securities fraud by the company and its executives, which could lead to significant investor losses.
- FDA Response Letter: On February 1, 2026, Pharming announced that the FDA issued a Complete Response Letter for its Joenja® supplemental New Drug Application, requesting additional pediatric pharmacokinetic data to ensure safety for lower weight children.
- Significant Stock Drop: Following the FDA's announcement, Pharming's American Depositary Receipt (ADR) price fell by $3.495, or 17.07%, closing at $16.975 per ADR on February 2, 2026, indicating market concerns about the company's future.
- Law Firm Background: Pomerantz LLP is a prominent firm in corporate and securities class litigation, established over 85 years ago, dedicated to fighting for the rights of victims of securities fraud and has historically recovered multimillion-dollar damages for class members.
See More
Pharming Group to Report Q4 and FY 2025 Results on March 12, 2026
- Earnings Report Announcement: Pharming Group has confirmed that it will release its preliminary (unaudited) financial results for Q4 and full year 2025 on March 12, 2026, aiming to communicate the latest financial status and strategic direction to investors and analysts.
- Conference Call Details: Management will host a conference call and webcast on the same day at 13:30 CET/08:30 am EDT, requiring participants to register in advance to obtain dial-in information and a unique PIN, thereby ensuring smooth proceedings and enhancing interaction with investors.
- Webcast Availability: The webcast will be accessible on Pharming's website under the Investors/Financial Documents section, with a replay available shortly after the event, ensuring that investors who cannot participate live can still access key information and enhancing transparency.
- Company Background: Pharming Group N.V. is a global biopharmaceutical company dedicated to developing and commercializing innovative medicines for rare, life-threatening diseases, supported by a professional team based in both the U.S. and the Netherlands, aiming to improve patient quality of life and drive long-term growth.
See More
Pomerantz LLP Investigates Pharming Group for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. regarding potential securities fraud or other unlawful business practices, with investors encouraged to contact Danielle Peyton to join the class action.
- FDA Complete Response Letter: On February 1, 2026, Pharming received a Complete Response Letter from the FDA concerning its supplemental New Drug Application for Joenja®, highlighting concerns about potential underexposure in lower weight pediatric patients and requesting additional pharmacokinetic data.
- Significant Stock Drop: Following the FDA's announcement, Pharming's American Depositary Receipt (ADR) price fell by $3.495, or 17.07%, closing at $16.975 per ADR on February 2, 2026, indicating market concerns regarding the company's future prospects.
- Law Firm Background: Pomerantz LLP is a premier law firm specializing in corporate, securities, and antitrust class litigation, founded over 85 years ago, and has a strong track record of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct.
See More
Pomerantz LLP Investigates Pharming Group for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of Pharming Group N.V. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and the company's reputation.
- FDA Response: On February 1, 2026, Pharming announced that the FDA issued a Complete Response Letter for its Joenja® supplemental New Drug Application, requesting additional pediatric pharmacokinetic data, potentially delaying product approval and impacting future revenues.
- Stock Price Decline: Following the FDA news, Pharming's American Depositary Receipt (ADR) price fell by $3.495, or 17.07%, closing at $16.975 on February 2, 2026, reflecting market concerns about the company's outlook.
- Legal Implications: The investigation by Pomerantz LLP could lead to a class action lawsuit, and if fraud is confirmed, it may result in significant damages for Pharming, further affecting its financial health and market performance.
See More
Pharming Reports Q4 2025 Earnings with Revenue Growth
- Earnings Highlights: Pharming's Q4 2025 GAAP EPS stands at $0.01, aligning with expectations, while revenue reaches $106.5 million, reflecting a 14.9% year-over-year growth and exceeding market expectations by $0.6 million, indicating the company's stable performance in the market.
- RUCONEST® Revenue Growth: RUCONEST® generated $86.7 million in revenue, marking a 9% increase compared to Q4 2024, highlighting sustained demand for the product and the company's competitive position in this segment.
- Strong Joenja® Performance: Joenja® saw a remarkable 53% revenue increase to $19.8 million in Q4, showcasing the product's market acceptance and the success of the sales strategy, which is expected to further drive overall company performance.
- Cash Flow and Future Outlook: Operating cash flow amounted to $10.7 million, up from $9.3 million in Q4 2024, while cash and cash equivalents rose from $168.9 million to $181.1 million; the 2026 total revenue guidance of $405 million to $425 million reflects the company's confidence in future growth prospects.
See More
Pharming Group Reports Strong Q4 2025 Earnings Growth
- Significant Revenue Growth: Pharming Group reported total revenues of $106.5 million in Q4 2025, reflecting a 15% year-over-year increase, while full-year revenues grew by 27% to $376.1 million, showcasing the company's strong growth potential in the biotech sector.
- Improved Profitability: The company achieved an operating profit of $26 million in 2025, a substantial turnaround from a loss in 2024, with Q4 operating cash flow reaching $55 million, enhancing financial stability and cash reserves compared to the end of 2024.
- Strong Product Performance: RUCONEST delivered a 26% global revenue growth, while Joenja reached $19.8 million in Q4 2025, marking a 53% increase year-over-year, indicating resilience in market competition and robust product demand.
- Optimistic Outlook: Pharming reaffirmed its 2026 revenue guidance of $405 million to $425 million, expecting continued growth for RUCONEST and Joenja despite new competitive pressures, with management expressing confidence in future market expansion and R&D investments.
See More
Pomerantz LLP Investigates Pharming Group for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Pharming Group N.V. regarding potential securities fraud by the company and its executives, which could lead to significant investor losses.
- FDA Response Letter: On February 1, 2026, Pharming announced that the FDA issued a Complete Response Letter for its Joenja® supplemental New Drug Application, requesting additional pediatric pharmacokinetic data to ensure safety for lower weight children.
- Significant Stock Drop: Following the FDA's announcement, Pharming's American Depositary Receipt (ADR) price fell by $3.495, or 17.07%, closing at $16.975 per ADR on February 2, 2026, indicating market concerns about the company's future.
- Law Firm Background: Pomerantz LLP is a prominent firm in corporate and securities class litigation, established over 85 years ago, dedicated to fighting for the rights of victims of securities fraud and has historically recovered multimillion-dollar damages for class members.
See More
Pharming Group to Report Q4 and FY 2025 Results on March 12, 2026
- Earnings Report Announcement: Pharming Group has confirmed that it will release its preliminary (unaudited) financial results for Q4 and full year 2025 on March 12, 2026, aiming to communicate the latest financial status and strategic direction to investors and analysts.
- Conference Call Details: Management will host a conference call and webcast on the same day at 13:30 CET/08:30 am EDT, requiring participants to register in advance to obtain dial-in information and a unique PIN, thereby ensuring smooth proceedings and enhancing interaction with investors.
- Webcast Availability: The webcast will be accessible on Pharming's website under the Investors/Financial Documents section, with a replay available shortly after the event, ensuring that investors who cannot participate live can still access key information and enhancing transparency.
- Company Background: Pharming Group N.V. is a global biopharmaceutical company dedicated to developing and commercializing innovative medicines for rare, life-threatening diseases, supported by a professional team based in both the U.S. and the Netherlands, aiming to improve patient quality of life and drive long-term growth.
See More
Pomerantz LLP Investigates Pharming Group for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. regarding potential securities fraud or other unlawful business practices, with investors encouraged to contact Danielle Peyton to join the class action.
- FDA Complete Response Letter: On February 1, 2026, Pharming received a Complete Response Letter from the FDA concerning its supplemental New Drug Application for Joenja®, highlighting concerns about potential underexposure in lower weight pediatric patients and requesting additional pharmacokinetic data.
- Significant Stock Drop: Following the FDA's announcement, Pharming's American Depositary Receipt (ADR) price fell by $3.495, or 17.07%, closing at $16.975 per ADR on February 2, 2026, indicating market concerns regarding the company's future prospects.
- Law Firm Background: Pomerantz LLP is a premier law firm specializing in corporate, securities, and antitrust class litigation, founded over 85 years ago, and has a strong track record of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct.
See More
Pomerantz LLP Investigates Pharming Group for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of Pharming Group N.V. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and the company's reputation.
- FDA Response: On February 1, 2026, Pharming announced that the FDA issued a Complete Response Letter for its Joenja® supplemental New Drug Application, requesting additional pediatric pharmacokinetic data, potentially delaying product approval and impacting future revenues.
- Stock Price Decline: Following the FDA news, Pharming's American Depositary Receipt (ADR) price fell by $3.495, or 17.07%, closing at $16.975 on February 2, 2026, reflecting market concerns about the company's outlook.
- Legal Implications: The investigation by Pomerantz LLP could lead to a class action lawsuit, and if fraud is confirmed, it may result in significant damages for Pharming, further affecting its financial health and market performance.
See More
